Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Growth in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 40,400 shares, a growth of 260.7% from the March 31st total of 11,200 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 55,500 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Affinity Asset Advisors LLC lifted its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 22.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 328,817 shares of the company’s stock after acquiring an additional 61,243 shares during the quarter. Affinity Asset Advisors LLC owned 2.06% of Context Therapeutics worth $497,000 at the end of the most recent quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

NASDAQ CNTX traded up $0.03 on Friday, hitting $1.41. 19,984 shares of the company’s stock were exchanged, compared to its average volume of 51,268. The firm’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.13. Context Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $1.69.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.07). Research analysts expect that Context Therapeutics will post -1.38 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price target on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.